{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T08:12:35Z","timestamp":1788595955026,"version":"build-2803163510"},"reference-count":147,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T00:00:00Z","timestamp":1788566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T00:00:00Z","timestamp":1788566400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Physiol Biochem"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s13105-026-01199-7","type":"journal-article","created":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T08:04:33Z","timestamp":1788595473000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Decoding dysbiosis: the role of gut microbiota in MASLD progression and emerging therapeutic interventions"],"prefix":"10.1007","volume":"82","author":[{"given":"Dinesh Mohan","family":"Swamikkannu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santhosha","family":"Dasarapu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanishk Dinesh","family":"Mohan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allimalarkodi","family":"Shanmugam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,5]]},"reference":[{"key":"1199_CR1","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/S2468-1253(22)00165-0","volume":"7","author":"K Riazi","year":"2022","unstructured":"Riazi K, Azhari H, Charette JH, Underwood FE, King JA, Afshar EE et al (2022) The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol 7:851\u2013861. https:\/\/doi.org\/10.1016\/S2468-1253(22)00165-0","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"1199_CR2","doi-asserted-by":"crossref","unstructured":"GBD 2015 Obesity Collaborators Health effects of overweight and obesity in 195 countries over 25 years. N Engl J Med. 2017;377:13\u201327. doi: 10.1056\/NEJMoa1614362.","DOI":"10.1056\/NEJMoa1614362"},{"key":"1199_CR3","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/S2213-8587(22)00003-1","volume":"10","author":"N Stefan","year":"2022","unstructured":"Stefan N, Cusi K (2022) A global view of the interplay between nonalcoholic fatty liver disease and diabetes. Lancet Diabetes Endocrinol 10:284\u2013296. https:\/\/doi.org\/10.1016\/S2213-8587(22)00003-1","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"Suppl","key":"1199_CR4","doi-asserted-by":"publisher","first-page":"S32","DOI":"10.3350\/cmh.2022.0365","volume":"29","author":"ML Teng","year":"2023","unstructured":"Teng ML, Ng CH, Huang DQ, Chan KE, Tan DJ, Lim WH, Yang JD, Tan E, Muthiah MD (2023) Global incidence and prevalence of nonalcoholic fatty liver disease. Clin Mol Hepatol 29(Suppl):S32\u2013S42. https:\/\/doi.org\/10.3350\/cmh.2022.0365","journal-title":"Clin Mol Hepatol"},{"key":"1199_CR5","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver (EASL). European Association for the Study of Diabetes (EASD). European Association for the Study of Obesity (EASO). EASL\u2013EASD\u2013EASO Clinical Practice Guidelines for the management of nonalcoholic fatty liver disease. J. Hepatol. 2016, 64, 1388\u20131402.","DOI":"10.1016\/j.jhep.2015.11.004"},{"key":"1199_CR6","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1002\/hep.29367","volume":"67","author":"N Chalasani","year":"2018","unstructured":"Chalasani N, Younossi Z, LaVine JE, Charlton M, Cusi K, Rinella M, Harrison SA, Brunt EM, Sanyal AJ (2018) The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology 67:328\u2013357","journal-title":"Hepatology"},{"key":"1199_CR7","doi-asserted-by":"publisher","unstructured":"Eslam M, Sanyal A.J, George J. International Consensus Panel. MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease. Gastroenterology 2020, 158, 1999\u20132014.e1. https:\/\/doi.org\/10.1053\/j.gastro.2019.11.312","DOI":"10.1053\/j.gastro.2019.11.312"},{"key":"1199_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcrc.2023.154436","volume":"79","author":"J Sung","year":"2024","unstructured":"Sung J, Rajendraprasad SS, Philbrick KL, Bauer BA, Gajic O, Shah A, Laudanski K, Bakken JS, Skalski J, Karnatovskaia LV (2024) The human gut microbiome in critical illness: disruptions, consequences, and therapeutic frontiers. J Crit Care 79:154436. https:\/\/doi.org\/10.1016\/j.jcrc.2023.154436","journal-title":"J Crit Care"},{"key":"1199_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jnutbio.2022.108991","volume":"105","author":"L Anto","year":"2022","unstructured":"Anto L, Blesso CN (2022) Interplay between diet, the gut microbiome, and atherosclerosis: role of dysbiosis and microbial metabolites on inflammation and disordered lipid metabolism. J Nutr Biochem 105:108991. https:\/\/doi.org\/10.1016\/j.jnutbio.2022.108991","journal-title":"J Nutr Biochem"},{"key":"1199_CR10","doi-asserted-by":"crossref","unstructured":"Dicks LMT. Gut Bacteria and Neurotransmitters. Microorganisms. 2022 Sep 14;10(9):1838. doi: 10.3390\/microorganisms10091838.","DOI":"10.3390\/microorganisms10091838"},{"key":"1199_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.946248","volume":"13","author":"A Christovich","year":"2022","unstructured":"Christovich A, Luo XM (2022) Gut microbiota, leaky gut, and autoimmune diseases. Front Immunol 13:946248. https:\/\/doi.org\/10.3389\/fimmu.2022.946248","journal-title":"Front Immunol"},{"key":"1199_CR12","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.nutres.2021.09.001","volume":"95","author":"VT Pham","year":"2021","unstructured":"Pham VT, Dold S, Rehman A, Bird JK, Steinert RE (2021) Vitamins, the gut microbiome and gastrointestinal health in humans. Nutr Res 95:35\u201353. https:\/\/doi.org\/10.1016\/j.nutres.2021.09.001","journal-title":"Nutr Res"},{"key":"1199_CR13","doi-asserted-by":"publisher","unstructured":"Witkowski M, Weeks TL, Hazen SL. Gut microbiota and cardiovascular disease. Circulation research. 2020 Jul 31;127(4):553\u2009\u2212\u200970. https:\/\/doi.org\/10.1161\/CIRCRESAHA.120.316242","DOI":"10.1161\/CIRCRESAHA.120.316242"},{"key":"1199_CR14","doi-asserted-by":"publisher","unstructured":"Ghaffari P, Shoaie S, & Nielsen LK Irritable bowel syndrome and microbiome; Switching from conventional diagnosis and therapies to personalized interventions. J Transl Med 20, 173 (2022). https:\/\/doi.org\/10.1186\/s12967-022-03365-z","DOI":"10.1186\/s12967-022-03365-z"},{"key":"1199_CR15","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1002\/hep.31065","volume":"72","author":"CL Mack","year":"2020","unstructured":"Mack CL, Adams D, Assis DN, Kerkar N, Manns MP, Mayo MJ et al (2020) Diagnosis and management of autoimmune hepatitis in adults and children: 2019 practice guidance and guidelines from the American Association for the Study of Liver Diseases. Hepatology 72:671\u2013722. https:\/\/doi.org\/10.1002\/hep.31065","journal-title":"Hepatology"},{"key":"1199_CR16","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1136\/gutjnl-2017-315259","volume":"67","author":"GM Hirschfield","year":"2018","unstructured":"Hirschfield GM, Dyson JK, Alexander G, Chapman MH, Collier J, H\u00fcbscher S et al (2018) The British Society of Gastroenterology\/UK-PBC primary biliary cholangitis treatment and management guidelines. Gut 67:1568\u201394. https:\/\/doi.org\/10.1136\/gutjnl-2017-315259","journal-title":"Gut"},{"key":"1199_CR17","doi-asserted-by":"crossref","unstructured":"Rabiee A, Silveira MG. Primary Sclerosing Cholangitis. Transl Gastroenterol Hepatol (2021) 6:29. doi: 10.21037\/tgh-20-266","DOI":"10.21037\/tgh-20-266"},{"key":"1199_CR18","doi-asserted-by":"crossref","unstructured":"Shaikh SD, Sun N, Canakis A, Park WY, Weber HC. Irritable Bowel Syndrome and the Gut Microbiome: A Comprehensive Review. J Clin Med. 2023 Mar 28;12(7):2558. doi: 10.3390\/jcm12072558.","DOI":"10.3390\/jcm12072558"},{"issue":"8","key":"1199_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.arcmed.2025.103335","volume":"56","author":"MM Ram\u00edrez-Mej\u00eda","year":"2025","unstructured":"Ram\u00edrez-Mej\u00eda MM, Ponciano-Rodr\u00edguez G, M\u00e9ndez-S\u00e1nchez N (2025) Implications of the liver-gut axis in liver disease: from mechanisms to therapeutic targets. Arch Med Res 56(8):103335","journal-title":"Arch Med Res"},{"key":"1199_CR20","doi-asserted-by":"crossref","unstructured":"Wang J, Wang X, Zhuo E, Chen B, Chan S. Gut-liver axis in liver disease: From basic science to clinical treatment (Review). Mol Med Rep. 2025 Jan;31(1):10. doi: 10.3892\/mmr.2024.13375.","DOI":"10.3892\/mmr.2024.13375"},{"key":"1199_CR21","doi-asserted-by":"publisher","unstructured":"Loomba R, Friedman SL, Shulman GI. Mechanisms and disease consequences of nonalcoholic fatty liver disease. Cell. 2021 May 13;184(10):2537-64. https:\/\/doi.org\/10.1016\/j.cell.2021.04.015","DOI":"10.1016\/j.cell.2021.04.015"},{"key":"1199_CR22","doi-asserted-by":"publisher","unstructured":"Aron-Wisnewsky J, Warmbrunn MV, Nieuwdorp M, Clement K. Nonalcoholic fatty liver disease: modulating gut microbiota to improve severity?. Gastroenterology. 2020 May 1;158(7):1881-98. https:\/\/doi.org\/10.1053\/j.gastro.2020.01.049","DOI":"10.1053\/j.gastro.2020.01.049"},{"key":"1199_CR23","doi-asserted-by":"publisher","unstructured":"Basuni AA, Sweed D, Elgazzar MF\u00a0et al. Exploring serum bile acids as potential noninvasive biomarkers for nonalcoholic fatty liver disease. Egypt Liver Journal 14, 70 (2024). https:\/\/doi.org\/10.1186\/s43066-024-00378-9","DOI":"10.1186\/s43066-024-00378-9"},{"key":"1199_CR24","doi-asserted-by":"crossref","unstructured":"Arab JP, Karpen SJ, Dawson PA, Arrese M, Trauner M. Bile acids and nonalcoholic fatty liver disease: Molecular insights and therapeutic perspectives. Hepatology. 2017 Jan;65(1):350\u2013362. doi: 10.1002\/hep.28709.","DOI":"10.1002\/hep.28709"},{"key":"1199_CR25","doi-asserted-by":"publisher","DOI":"10.2147\/dmso.s429825","author":"YK Zhao","year":"2023","unstructured":"Zhao YK, Zhu XD, Liu R, Yang X, Liang YL, Wang Y (2023) The role of PPAR\u03b3 gene polymorphisms, gut microbiota in type 2 diabetes: current progress and future prospects. Diabetes Metab Syndr Obes. https:\/\/doi.org\/10.2147\/dmso.s429825","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"12","key":"1199_CR26","doi-asserted-by":"publisher","DOI":"10.3390\/nu15122675","volume":"15","author":"C Di Rosa","year":"2023","unstructured":"Di Rosa C, Di Francesco L, Spiezia C, Khazrai YM (2023) Effects of animal and vegetable proteins on gut microbiota in subjects with overweight or obesity. Nutrients 15(12):2675","journal-title":"Nutrients"},{"key":"1199_CR27","doi-asserted-by":"crossref","unstructured":"Feng W, Liu J, Cheng H, Zhang D, Tan Y, Peng C. Dietary compounds in modulation of gut microbiota-derived metabolites. Front Nutr. 2022 Jul 19;9:939571. doi: 10.3389\/fnut.2022.939571.","DOI":"10.3389\/fnut.2022.939571"},{"key":"1199_CR28","doi-asserted-by":"crossref","unstructured":"Pham NHT, Joglekar MV, Wong WKM, Nassif NT, Simpson AM, Hardikar AA. Short-chain fatty acids and insulin sensitivity: a systematic review and meta-analysis. Nutr Rev. 2024 Jan 10;82(2):193\u2013209. doi: 10.1093\/nutrit\/nuad042.","DOI":"10.1093\/nutrit\/nuad042"},{"key":"1199_CR29","doi-asserted-by":"publisher","unstructured":"Meiyi Z, Jing S, Cheng-Yang W, Le S, Weibing D, Yunxia L, Mengping C, Max RW, Jiqiu W, Ji W, Wen-Jun G, Xiangbing Q, Aldons JL, Zhaoping L, Weiqing W, Guang N, Xia Y, David TC, Yibin W, Haipeng S. Targeting BCAA Catabolism to Treat Obesity-Associated Insulin Resistance. Diabetes 1 September 2019; 68 (9): 1730\u20131746. https:\/\/doi.org\/10.2337\/db18-0927","DOI":"10.2337\/db18-0927"},{"key":"1199_CR30","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.coi.2020.12.001","volume":"70","author":"A Fiore","year":"2021","unstructured":"Fiore A, Murray PJ (2021) Tryptophan and indole metabolism in immune regulation. Curr Opin Immunol 70:7\u201314","journal-title":"Curr Opin Immunol"},{"key":"1199_CR31","unstructured":"Arya P, Sharma V, Singh P, Thapliyal S, Sharma M. Bacterial endotoxin-lipopolysaccharide role in inflammatory diseases: An overview. Iran J Basic Med Sci. 2025;28(5):553\u2013564. doi: 10.22038\/ijbms.2025.82302.17799."},{"key":"1199_CR32","doi-asserted-by":"publisher","unstructured":"Sasidharan PS, Ashraf AP. Gut Microbiota and Metabolic Health: From Dysbiosis to Therapeutics. Diabetes Ther (2026). https:\/\/doi.org\/10.1007\/s13300-026-01851-x","DOI":"10.1007\/s13300-026-01851-x"},{"key":"1199_CR33","doi-asserted-by":"publisher","unstructured":"Slevin E, Baiocchi L, Wu N, Ekser B, Sato K, Lin E, Ceci L, Chen L, Lorenzo SR, Xu W, Kyritsi K. Kupffer cells: inflammation pathways and cell-cell interactions in alcohol-associated liver disease. The American Journal of Pathology. 2020 Nov 1;190(11):2185-93. https:\/\/doi.org\/10.1016\/j.ajpath.2020.08.014","DOI":"10.1016\/j.ajpath.2020.08.014"},{"key":"1199_CR34","doi-asserted-by":"publisher","unstructured":"Broz P, Dixit VM. Inflammasomes: mechanism of assembly, regulation and signalling. Nature Reviews Immunology. 2016 Jul;16(7):407\u2009\u2212\u200920. https:\/\/doi.org\/10.1038\/nri.2016.58","DOI":"10.1038\/nri.2016.58"},{"key":"1199_CR35","doi-asserted-by":"crossref","unstructured":"de Carvalho Ribeiro M, Szabo G. Role of the Inflammasome in Liver Disease. Annu Rev Pathol. 2022 Jan 24;17:345\u2013365. doi: 10.1146\/annurev-pathmechdis-032521-102529.","DOI":"10.1146\/annurev-pathmechdis-032521-102529"},{"key":"1199_CR36","doi-asserted-by":"publisher","unstructured":"O\u2019Riordan KJ, Collins MK, Moloney GM, Knox EG, Aburto MR, F\u00fclling C, Morley SJ, Clarke G, Schellekens H, Cryan JF. Short chain fatty acids: Microbial metabolites for gut-brain axis signalling. Molecular and Cellular Endocrinology. 2022 Apr 15;546:111572. https:\/\/doi.org\/10.1016\/j.mce.2022.111572","DOI":"10.1016\/j.mce.2022.111572"},{"key":"1199_CR37","doi-asserted-by":"crossref","unstructured":"Amabebe E, Robert FO, Agbalalah T, Orubu ESF. Microbial dysbiosis-induced obesity: role of gut microbiota in homoeostasis of energy metabolism. Br J Nutr. (2020) 123:1127\u201337. doi: 10.1017\/S0007114520000380","DOI":"10.1017\/S0007114520000380"},{"key":"1199_CR38","doi-asserted-by":"publisher","unstructured":"Duan H, Wang L, Huangfu M, Li H. The impact of microbiota-derived short-chain fatty acids on macrophage activities in disease: Mechanisms and therapeutic potentials. Biomedicine & Pharmacotherapy. 2023 Sep 1;165:115276. https:\/\/doi.org\/10.1016\/j.biopha.2023.115276","DOI":"10.1016\/j.biopha.2023.115276"},{"key":"1199_CR39","doi-asserted-by":"crossref","unstructured":"Beisner J, Filipe Rosa L, Kaden-Volynets V, Stolzer I, G\u00fcnther C, Bischoff SC.Prebiotic inulin and sodium butyrate attenuate obesity-induced intestinal barrier dysfunction by induction of antimicrobial peptides. Front Immunol. (2021) 12:678360. doi: 10.3389\/fimmu.2021.678360","DOI":"10.3389\/fimmu.2021.678360"},{"key":"1199_CR40","doi-asserted-by":"publisher","unstructured":"Silva YP, Bernardi A, Frozza RL. The role of short-chain fatty acids from gut microbiota in gut-brain communication. Frontiers in endocrinology. 2020 Jan 31;11:508738. https:\/\/doi.org\/10.3389\/fendo.2020.00025","DOI":"10.3389\/fendo.2020.00025"},{"key":"1199_CR41","doi-asserted-by":"crossref","unstructured":"Jasirwan COM, Lesmana CRA, Hasan I, Sulaiman AS, Gani RA. The role of gut microbiota in non-alcoholic fatty liver disease: pathways of mechanisms. Biosci Microbiota Food Health. 2019;38(3):81\u201388. doi: 10.12938\/bmfh.18-032.","DOI":"10.12938\/bmfh.18-032"},{"key":"1199_CR42","doi-asserted-by":"publisher","unstructured":"Gorelick J, Assa-Glazer T, Zandani G et al. THC and CBD affect metabolic syndrome parameters including microbiome in mice fed high fat-cholesterol diet. J Cannabis Res 4, 27 (2022). https:\/\/doi.org\/10.1186\/s42238-022-00137-w","DOI":"10.1186\/s42238-022-00137-w"},{"issue":"5","key":"1199_CR43","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1007\/s10620-016-4054-0","volume":"61","author":"S Softic","year":"2016","unstructured":"Softic S, Cohen DE, Kahn CR (2016) Role of dietary fructose and hepatic de novo lipogenesis in fatty liver disease. Dig Dis Sci 61(5):1282\u201393. https:\/\/doi.org\/10.1007\/s10620-016-4054-0","journal-title":"Dig Dis Sci"},{"issue":"3","key":"1199_CR44","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.aaf.2023.05.004","volume":"9","author":"U Mukherjee","year":"2024","unstructured":"Mukherjee U, Maitra S (2024) Impact of metabolic disrupting chemicals on redox homeostasis, energy sensors, receptor modulation, and hormone metabolism: a comparative account in teleost and mammalian model organisms. Aquac Fish 9(3):455\u201385","journal-title":"Aquac Fish"},{"key":"1199_CR45","doi-asserted-by":"publisher","unstructured":"Vallianou NG, Kounatidis D, Psallida S et al. The Interplay Between Dietary Choline and Cardiometabolic Disorders: A Review of Current Evidence. Curr Nutr Rep 13, 152\u2013165 (2024). https:\/\/doi.org\/10.1007\/s13668-024-00521-3","DOI":"10.1007\/s13668-024-00521-3"},{"key":"1199_CR46","doi-asserted-by":"crossref","unstructured":"Arias N, Arboleya S, Allison J, Kaliszewska A, Higarza SG, Gueimonde M et al. The relationship between choline bioavailability from diet, intestinal microbiota composition, and its modulation of human diseases. Nutrients. (2020) 12:2340. doi: 10.3390\/nu12082340","DOI":"10.3390\/nu12082340"},{"key":"1199_CR47","doi-asserted-by":"crossref","unstructured":"Chai C, Chen L, Deng MG, Liang Y, Liu F, Nie JQ. Dietary choline intake and non-alcoholic fatty liver disease (NAFLD) in U.S. adults: National Health and Nutrition Examination Survey (NHANES) 2017\u20132018. Eur J Clin Nutr. (2023) 77:1160\u20136. doi: 10.1038\/s41430-023-01336-1","DOI":"10.1038\/s41430-023-01336-1"},{"key":"1199_CR48","doi-asserted-by":"crossref","unstructured":"Chan SM, Martins VF, Marsh K, Wang K, Weeks JT, Han A, Yin M, Fowler KJ, Sirlin CB, Hong CW. Imaging Evaluation for Steatotic Liver Disease. Korean J Radiol. 2026 Feb;27(2):137\u2013151. doi: 10.3348\/kjr.2025.0966.","DOI":"10.3348\/kjr.2025.0966"},{"key":"1199_CR49","doi-asserted-by":"crossref","unstructured":"Wilson MP, Singh R, Mehta S, Murad MH, Fung C, Low G. Comparing FIB-4, VCTE, pSWE, 2D-SWE, and MRE Thresholds and Diagnostic Accuracies for Detecting Hepatic Fibrosis in Patients with MASLD: A Systematic Review and Meta-Analysis. Diagnostics (Basel). 2025 Jun 24;15(13):1598. doi: 10.3390\/diagnostics15131598.","DOI":"10.3390\/diagnostics15131598"},{"key":"1199_CR50","unstructured":"Kazi IN, Kuo L, Tsai E. Noninvasive Methods for Assessing Liver Fibrosis and Steatosis. Gastroenterol Hepatol (N Y). 2024 Jan;20(1):21\u201329."},{"key":"1199_CR51","doi-asserted-by":"crossref","unstructured":"Bourgonje AR, van den Berg EH, Kieneker LM, Nilsen T, Hidden C, Bakker SJL, Blokzijl H, Dullaart RPF, van Goor H, Abdulle AE. Plasma Calprotectin Levels Associate with Suspected Metabolic-Associated Fatty Liver Disease and All-Cause Mortality in the General Population. Int J Mol Sci. 2022 Dec 11;23(24):15708. doi: 10.3390\/ijms232415708.","DOI":"10.3390\/ijms232415708"},{"key":"1199_CR52","doi-asserted-by":"publisher","unstructured":"Demirba\u015f F, \u00c7altepe G, Comba A, Abbasguliyev H, Uyar NY, Kalayc\u0131 AG. Association of obesity and non-alcoholic fatty liver disease with the fecal calprotectin level in children. Arab Journal of Gastroenterology. 2020 Dec 1;21(4):211-5. https:\/\/doi.org\/10.1016\/j.ajg.2020.09.003","DOI":"10.1016\/j.ajg.2020.09.003"},{"issue":"12","key":"1199_CR53","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics12122935","volume":"12","author":"C Fierbinteanu-Braticevici","year":"2022","unstructured":"Fierbinteanu-Braticevici C, Calin-Necula A-M, Enciu V-T, Goran L, Pantea Stoian A, Ancuta I, Viasu O, Moldoveanu AC (2022) The role of noninvasive 13C-octanoate breath test in assessing the diagnosis of nonalcoholic steatohepatitis. Diagnostics (Basel) 12(12):2935. https:\/\/doi.org\/10.3390\/diagnostics12122935","journal-title":"Diagnostics (Basel)"},{"key":"1199_CR54","doi-asserted-by":"crossref","unstructured":"Angelini G, Panunzi S, Castagneto-Gissey L, Pellican\u00f2 F, De Gaetano A, Pompili M, Riccardi L, Garcovich M, Raffaelli M, Ciccoritti L, Verrastro O, Russo MF, Vecchio FM, Casella G, Casella-Mariolo J, Papa L, Marini PL, Rubino F, le Roux CW, Bornstein S, Mingrone G. Accurate liquid biopsy for the diagnosis of non-alcoholic steatohepatitis and liver fibrosis. Gut. 2023 Feb;72(2):392\u2013403. doi: 10.1136\/gutjnl-2022-327498","DOI":"10.1136\/gutjnl-2022-327498"},{"issue":"5","key":"1199_CR55","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/s41575-020-0269-9","volume":"17","author":"J Aron-Wisnewsky","year":"2020","unstructured":"Aron-Wisnewsky J, Vigliotti C, Witjes J, Le P, Holleboom AG, Verheij J, Nieuwdorp M, Cl\u00e9ment K (2020) Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders. Nat Rev Gastroenterol Hepatol 17(5):279\u201397","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"1199_CR56","doi-asserted-by":"crossref","unstructured":"Balakrishnan J, Kannan S, Arivazhangan GB, Ramachandran N, Sundaramoorthy VG. Understanding the Interconnected Roles of Gut Microbiota and Metabolomic Profiles in Alcoholic Liver Disease Pathophysiology and Their Potential for Innovative Treatment Strategies. Medicine in Microecology. 2025 Oct 17:100154.","DOI":"10.1016\/j.medmic.2025.100154"},{"key":"1199_CR57","doi-asserted-by":"crossref","unstructured":"Chee NMZ et al. Vitamin E improves serum markers and histology in adults with metabolic dysfunction-associated steatotic liver disease: Systematic review and meta-analysis. JGH. 2024; doi.org\/10.1111\/jgh.16723.","DOI":"10.1111\/jgh.16723"},{"key":"1199_CR58","volume":"2024","author":"H Wen","year":"2024","unstructured":"Wen H, Deng H, Yang L, Li L, Lin J, Zheng P, Bjelakovic M, Ji G (2024) Vitamin E for people with non-alcoholic fatty liver disease. Cochrane Database Syst Rev 2024:CD015033","journal-title":"Cochrane Database Syst Rev"},{"key":"1199_CR59","doi-asserted-by":"crossref","unstructured":"Pereira IV, de Oliveira AB, Zitelli PM, Barbieri LA, Cardoso AC, Monteiro MJ, de Oliveira JS, Stefano JT, Altikes R, Reis AL, de Figueiredo Mendes C. Long-term pioglitazone use in MASLD patients: insights from a multicentric preliminary study. Clinics. 2025 Jan 1;80:100737.","DOI":"10.1016\/j.clinsp.2025.100737"},{"key":"1199_CR60","doi-asserted-by":"crossref","unstructured":"Kumar A. MASLD Pharmacotherapy: Current Standards, Emerging Treatments, and Practical Guidance for Indian Physicians. The Journal of the Association of Physicians of India. 2025 Jul 1;73(7):e45-60.","DOI":"10.59556\/japi.73.1058"},{"key":"1199_CR61","doi-asserted-by":"publisher","unstructured":"Bandyopadhyay S, Samajdar SS, Das S. Effects of saroglitazar in the treatment of non-alcoholic fatty liver disease or non-alcoholic steatohepatitis: A systematic review and meta-analysis. Clinics and Research in Hepatology and Gastroenterology. 2023 Jun 26:102174. https:\/\/doi.org\/10.1016\/j.clinre.2023.102174","DOI":"10.1016\/j.clinre.2023.102174"},{"key":"1199_CR62","doi-asserted-by":"crossref","unstructured":"Choi YJ, Johnson JD, Lee JJ, Song J, Matthews M, Hellerstein MK, McWherter CA. Seladelpar combined with complementary therapies improves fibrosis, inflammation, and liver injury in a mouse model of nonalcoholic steatohepatitis. Am J PhysiolGastrointest Liver Physiol. 2024 Feb 1;326(2):G120-G132. doi: 10.1152\/ajpgi.00158.2023.","DOI":"10.1152\/ajpgi.00158.2023"},{"key":"1199_CR63","doi-asserted-by":"publisher","unstructured":"Drygalski K (2025). Pharmacological Treatment of MASLD: Contemporary Treatment and Future Perspectives. International Journal of Molecular Sciences, 26(13), 6518. https:\/\/doi.org\/10.3390\/ijms26136518","DOI":"10.3390\/ijms26136518"},{"key":"1199_CR64","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1111\/apt.14492","volume":"47","author":"B Hameed","year":"2018","unstructured":"Hameed B, Terrault NA, Gill RM, Loomba R, Chalasani N, Hoofnagle JH, Van Natta ML (2018) Clinical and metabolic effects associated with weight changes and obeticholic acid in non-alcoholic steatohepatitis. Aliment Pharmacol Ther 47:645\u2013656","journal-title":"Aliment Pharmacol Ther"},{"key":"1199_CR65","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.jhep.2019.10.006","volume":"72","author":"MS Siddiqui","year":"2020","unstructured":"Siddiqui MS, Van Natta ML, Connelly MA, Vuppalanchi R, Neuschwander-Tetri BA, Tonascia J, Guy C, Loomba R, Dasarathy S, Wattacheril J et al (2020) Impact of obeticholic acid on the lipoprotein profile in patients with non-alcoholic steatohepatitis. J Hepatol 72:25\u201333","journal-title":"J Hepatol"},{"key":"1199_CR66","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.jhep.2022.10.027","volume":"78","author":"W Shen","year":"2023","unstructured":"Shen W, Middleton MS, Cunha GM, Delgado TI, Wolfson T, Gamst A, Fowler KJ, Alazraki A, Trout AT, Ohliger MA et al (2023) Changes in abdominal adipose tissue depots assessed by MRI correlate with hepatic histologic improvement in non-alcoholic steatohepatitis. J Hepatol 78:238\u2013246","journal-title":"J Hepatol"},{"key":"1199_CR67","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.jhep.2022.10.023","volume":"78","author":"V Ratziu","year":"2023","unstructured":"Ratziu V, Harrison SA, Loustaud-Ratti V, Bureau C, Lawitz E, Abdelmalek M, Alkhouri N, Francque S, Girma H, Darteil R et al (2023) Hepatic and renal improvements with FXR agonist vonafexor in individuals with suspected fibrotic NASH. J Hepatol 78:479\u2013492","journal-title":"J Hepatol"},{"key":"1199_CR68","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.jhep.2021.10.018","volume":"76","author":"V Ratziu","year":"2022","unstructured":"Ratziu V, Rinella ME, Neuschwander-Tetri BA, Lawitz E, Denham D, Kayali Z, Sheikh A, Kowdley KV, Desta T, Elkhashab M et al (2022) EDP-305 in patients with NASH: a phase II double-blind placebo-controlled dose-ranging study. J Hepatol 76:506\u2013517","journal-title":"J Hepatol"},{"issue":"1","key":"1199_CR69","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1002\/hep.31205","volume":"72","author":"K Patel","year":"2020","unstructured":"Patel K, Harrison SA, Elkhashab M, Trotter JF, Herring R, Rojter SE, Kayali Z, Wong VW, Greenbloom S, Jayakumar S, Shiffman ML (2020) Cilofexor, a nonsteroidal FXR agonist, in patients with noncirrhotic NASH: a phase 2 randomized controlled trial. Hepatology 72(1):58\u201371","journal-title":"Hepatology"},{"key":"1199_CR70","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.tem.2017.11.002","volume":"29","author":"A Molinaro","year":"2018","unstructured":"Molinaro A, Wahlstr\u00f6m A, Marschall H-U (2018) Role of bile acids in metabolic control. Trends Endocrinol Metab 29:31\u201341","journal-title":"Trends Endocrinol Metab"},{"key":"1199_CR71","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1002\/med.21991","volume":"44","author":"K Wang","year":"2023","unstructured":"Wang K, Zhang Y, Wang G, Hao H, Wang H (2023) FXR agonists for MASH therapy: lessons and perspectives from obeticholic acid. Med Res Rev 44:568\u2013586","journal-title":"Med Res Rev"},{"key":"1199_CR72","doi-asserted-by":"publisher","first-page":"2184","DOI":"10.1016\/S0140-6736(19)33041-7","volume":"394","author":"ZM Younossi","year":"2019","unstructured":"Younossi ZM, Ratziu V, Loomba R, Rinella M, Anstee QM, Goodman Z, Bedossa P, Geier A, Beckebaum S, Newsome PN et al (2019) Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. Lancet 394:2184\u20132196","journal-title":"Lancet"},{"key":"1199_CR73","doi-asserted-by":"crossref","unstructured":"Marchiano S, Biagioli M, Roselli R, Zampella A, Di Giorgio C, Bordoni M et al. (2022). Beneficial effects of UDCA and norUDCA in a rodent model of steatosis are linked to modulation of GPBAR1\/FXR signaling. Biochim. Biophys. Acta Mol. Cell Biol. Lipids 1867 (11), 159218. doi:10.1016\/j.bbalip.2022.159218","DOI":"10.1016\/j.bbalip.2022.159218"},{"key":"1199_CR74","doi-asserted-by":"crossref","unstructured":"Xie P, Peng Y, Qiu L (2022). Responsive oligochitosan nano-vesicles with ursodeoxycholic acid and exenatide for NAFLD synergistic therapy via SIRT1. Carbohydr. Polym. 288, 119388. doi:10.1016\/j.carbpol.2022.119388","DOI":"10.1016\/j.carbpol.2022.119388"},{"key":"1199_CR75","doi-asserted-by":"crossref","unstructured":"Marchian\u00f2 S, Biagioli M, Morretta E, Di Giorgio C, Roselli R, Bordoni M et al. (2023). Combinatorial therapy with BAR502 and UDCA resets FXR and GPBAR1 signaling and reverses liver histopathology in a model of NASH. Sci. Rep. 13 (1), 1602. doi:10.1038\/s41598-023-28647-4","DOI":"10.1038\/s41598-023-28647-4"},{"key":"1199_CR76","doi-asserted-by":"crossref","unstructured":"Nevola R, Epifani R, Imbriani S, Tortorella G, Aprea C, Galiero R, Rinaldi L, Marfella R, Sasso FC. GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives. Int J Mol Sci. 2023 Jan 15;24(2):1703. doi: 10.3390\/ijms24021703.","DOI":"10.3390\/ijms24021703"},{"key":"1199_CR77","doi-asserted-by":"crossref","unstructured":"Davies MJ, Aroda VR, Collins BS, Gabbay RA, Green J, Maruthur NM, Rosas SE, Del Prato S, Mathieu C, Mingrone G et al. Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) Diabetes Care. 2022;45:2753\u20132786. doi: 10.2337\/dci22-0034.","DOI":"10.2337\/dci22-0034"},{"key":"1199_CR78","doi-asserted-by":"crossref","unstructured":"Mao T, Zhang C, Yang S, Bi Y, Li M, Yu J. Semaglutide alters gut microbiota and improves NAFLD in db\/db mice. Biochem Biophys Res Commun. 2024;710:149882. doi: 10.1016\/j.bbrc.2024.149882.","DOI":"10.1016\/j.bbrc.2024.149882"},{"key":"1199_CR79","doi-asserted-by":"crossref","unstructured":"Niu S, Chen SC, Wang CX, Yue L, Wang SQ. Metabolic and hepatic effects of semaglutide and empagliflozin on metabolic dysfunction-associated steatotic liver disease mice. World J Hepatol. 2025 Oct 27;17(10):110402. doi: 10.4254\/wjh.v17.i10.110402.","DOI":"10.4254\/wjh.v17.i10.110402"},{"issue":"3","key":"1199_CR80","doi-asserted-by":"publisher","first-page":"101568","DOI":"10.1016\/j.clinre.2020.10.012","volume":"45","author":"MS Kalogirou","year":"2021","unstructured":"Kalogirou MS, Patoulias D, Haidich AB, Akriviadis E, Sinakos E (2021) Liraglutide in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis of randomized controlled trials. Clin Res Hepatol Gastroenterol 45(3):101568","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"1199_CR81","doi-asserted-by":"crossref","unstructured":"Loomba R, Hartman ML, Lawitz EJ, Vuppalanchi R, Boursier J, Bugianesi E, Yoneda M, Behling C, Cummings OW, Tang Y, Brouwers B. Tirzepatide for Metabolic Dysfunction\u2013Associated Steatohepatitis with Liver Fibrosis. New England Journal of Medicine. 2024 Jun 8. DOI: 10.1056\/NEJMoa2401943","DOI":"10.1056\/NEJMoa2401943"},{"key":"1199_CR82","doi-asserted-by":"publisher","unstructured":"Shankar SS, Daniels SJ, Robertson D, Sarv J, S\u00e1nchez J, Carter D, Jermutus L, Challis B, Sanyal AJ. Safety and Efficacy of Novel Incretin Co-agonist Cotadutide in Biopsy-proven Noncirrhotic MASH With Fibrosis. Clinical Gastroenterology and Hepatology. 2024 May 9. https:\/\/doi.org\/10.1016\/j.cgh.2024.04.017","DOI":"10.1016\/j.cgh.2024.04.017"},{"key":"1199_CR83","doi-asserted-by":"publisher","unstructured":"Lee J, Hong SW, Kim MJ, Moon SJ, Kwon H, Park SE, Rhee EJ, Lee WY. Dulaglutide ameliorates palmitic acid-induced hepatic steatosis by activating FAM3A signaling pathway. Endocrinology and Metabolism. 2022 Feb 9;37(1):74\u201383. DOI: https:\/\/doi.org\/10.3803\/EnM.2021.1293","DOI":"10.3803\/EnM.2021.1293"},{"key":"1199_CR84","doi-asserted-by":"crossref","unstructured":"Androutsakos T, Nasiri-Ansari N, Bakasis AD, Kyrou I, Efstathopoulos ER, Eva HS et al. SGLT-2 inhibitors in NAFLD: expanding their role beyond diabetes and cardioprotection. Int J Mol Sci. (2022) 23:3107. doi: 10.3390\/ijms23063107,","DOI":"10.3390\/ijms23063107"},{"key":"1199_CR85","doi-asserted-by":"crossref","unstructured":"Xu B, Li S, Kang B, Zhou J. The current role of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus management. Cardiovasc Diabetol. (2022) 21:83. doi: 10.1186\/s12933-022-01512-w,","DOI":"10.1186\/s12933-022-01512-w"},{"key":"1199_CR86","doi-asserted-by":"crossref","unstructured":"Jang H, Kim Y, Lee DH, Joo SK, Koo BK, Lim S et al. Outcomes of various classes of oral antidiabetic drugs on nonalcoholic fatty liver disease. JAMA Intern Med. (2024) 184:375\u201383. doi: 10.1001\/jamainternmed.2023.8029,","DOI":"10.1001\/jamainternmed.2023.8029"},{"issue":"4","key":"1199_CR87","doi-asserted-by":"publisher","DOI":"10.5493\/wjem.v15.i4.106403","volume":"15","author":"P Anirvan","year":"2025","unstructured":"Anirvan P, Giri S, Malakar S, Praharaj DL (2025) Role of sodium-glucose cotransporter 2 inhibitors in liver diseases. World J Exp Med 15(4):106403","journal-title":"World J Exp Med"},{"issue":"2","key":"1199_CR88","doi-asserted-by":"publisher","first-page":"285","DOI":"10.3803\/EnM.2024.203","volume":"39","author":"SW Cho","year":"2024","unstructured":"Cho SW (2024) Selective agonists of thyroid hormone receptor beta: promising tools for the treatment of nonalcoholic fatty liver disease. Endocrinol Metab 39(2):285\u20137","journal-title":"Endocrinol Metab"},{"issue":"7","key":"1199_CR89","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1210\/clinem\/dgad072","volume":"108","author":"L Li","year":"2023","unstructured":"Li L, Song Y, Shi Y, Sun L (2023) Thyroid hormone receptor-\u03b2 agonists in NAFLD therapy: possibilities and challenges. J Clin Endocrinol Metab 108(7):1602\u20131613. https:\/\/doi.org\/10.1210\/clinem\/dgad072","journal-title":"J Clin Endocrinol Metab"},{"key":"1199_CR90","doi-asserted-by":"crossref","unstructured":"Zhang R, Yan Z, Zhong H, Luo R, Liu W, Xiong S, Liu Q, Liu M. Gut microbial metabolites in MASLD: Implications of mitochondrial dysfunction in the pathogenesis and treatment. Hepatol Commun. 2024 Jul 5;8(7):e0484. doi: 10.1097\/HC9.0000000000000484.","DOI":"10.1097\/HC9.0000000000000484"},{"key":"1199_CR91","doi-asserted-by":"publisher","unstructured":"Maftei, NM, Raileanu CR, Balta AA, Ambrose L, Boev M, Marin DB, & Lisa EL (2024). The Potential Impact of Probiotics on Human Health: An Update on Their Health-Promoting Properties. Microorganisms, 12(2), 234. https:\/\/doi.org\/10.3390\/microorganisms12020234","DOI":"10.3390\/microorganisms12020234"},{"key":"1199_CR92","doi-asserted-by":"crossref","unstructured":"Soemarie YB, Milanda T, Barliana MI. Fermented foods as probiotics: A review. Journal of Advanced Pharmaceutical Technology & Research. 2021 Oct 1;12(4):335-9. DOI: 10.4103\/japtr.japtr_116_21","DOI":"10.4103\/japtr.japtr_116_21"},{"key":"1199_CR93","doi-asserted-by":"crossref","unstructured":"Sabirin F, Lim SM, Neoh CF, Ramasamy K. Hepatoprotection of probiotics against non-alcoholic fatty liver disease in vivo: A systematic review. Front Nutr. (2022) 9:844374. doi: 10.3389\/fnut.2022.844374","DOI":"10.3389\/fnut.2022.844374"},{"key":"1199_CR94","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1177\/1756283X16645055","volume":"9","author":"D Briskey","year":"2016","unstructured":"Briskey D, Heritage M, Jaskowski LA, Peake J, Gobe G, Subramaniam VN et al (2016) Probiotics modify tight-junction proteins in an animal model of nonalcoholic fatty liver disease. Ther Adv Gastroenterol 9:463\u201372. https:\/\/doi.org\/10.1177\/1756283X16645055","journal-title":"Ther Adv Gastroenterol"},{"key":"1199_CR95","doi-asserted-by":"crossref","unstructured":"Okubo H, Sakoda H, Kushiyama A, Fujishiro M, Nakatsu Y, Fukushima T et al. Lactobacillus casei strain Shirota protects against nonalcoholic steatohepatitis development in a rodent model. Am J Physiol Gastrointest Liver Physiol. (2013) 305: G911\u20138. doi: 10.1152\/ajpgi.00225.2013","DOI":"10.1152\/ajpgi.00225.2013"},{"key":"1199_CR96","doi-asserted-by":"crossref","unstructured":"Wagnerberger S, Spruss A, Kanuri G, Stahl C, Schr\u00f6der M, Vetter W et al. Lactobacillus casei Shirota protects from fructose-induced liver steatosis: a mouse model. J Nutr Biochem. (2013) 24:531\u20138. doi: 10.1016\/j.jnutbio.2012.01.014","DOI":"10.1016\/j.jnutbio.2012.01.014"},{"key":"1199_CR97","doi-asserted-by":"crossref","unstructured":"Park EJ, Lee YS, Kim SM, Park GS, Lee YH, Jeong DY et al. Beneficial effects of lactobacillus plantarum strains on non-alcoholic fatty liver disease in high fat\/high fructose diet-fed rats. Nutrients. (2020) 12:542. doi: 10.3390\/nu12020542","DOI":"10.3390\/nu12020542"},{"key":"1199_CR98","doi-asserted-by":"crossref","unstructured":"Kim B, Park KY, Ji Y, Park S, Holzapfel W, Hyun CK. Protective effects of Lactobacillus rhamnosus GG against dyslipidemia in high-fat diet-induced obese mice. Biochem Biophys Res Commun. (2016) 473:530\u20136. doi: 10.1016\/j.bbrc.2016.03.107","DOI":"10.1016\/j.bbrc.2016.03.107"},{"key":"1199_CR99","doi-asserted-by":"crossref","unstructured":"Liu Q, Liu Y, Li F, Gu Z, Liu M, Shao T, et al. Probiotic culture supernatant improves metabolic function through FGF21-adiponectin pathway in mice. J Nutr Biochem. (2020) 75:108256. doi: 10.1016\/j.jnutbio.2019.108256","DOI":"10.1016\/j.jnutbio.2019.108256"},{"key":"1199_CR100","doi-asserted-by":"crossref","unstructured":"Sohn W, Jun DW, Lee KN, Lee HL, Lee OY, Choi HS et al. Lactobacillus paracasei induces M2-dominant kupffer cell polarization in a mouse model of nonalcoholic steatohepatitis. Dig Dis Sci. (2015) 60:3340\u201350. doi: 10.1007\/s10620-015-3770-1","DOI":"10.1007\/s10620-015-3770-1"},{"key":"1199_CR101","doi-asserted-by":"crossref","unstructured":"Xin J, Zeng D, Wang H, Ni X, Yi D, Pan K et al. Preventing non-alcoholic fatty liver disease through Lactobacillus johnsonii BS15 by attenuating inflammation and mitochondrial injury and improving gut environment in obese mice. Appl Microbiol Biotechnol. (2014) 98:6817\u201329. doi: 10.1007\/s00253-014-5752-1","DOI":"10.1007\/s00253-014-5752-1"},{"key":"1199_CR102","doi-asserted-by":"crossref","unstructured":"Zhao Z, Chen L, Zhao Y, Wang C, Duan C, Yang G et al. Lactobacillus plantarum NA136 ameliorates nonalcoholic fatty liver disease by modulating gut microbiota, improving intestinal barrier integrity, and attenuating inflammation. Appl Microbiol Biotechnol. (2020) 104:5273\u201382. doi: 10.1007\/s00253-020-10633-9","DOI":"10.1007\/s00253-020-10633-9"},{"key":"1199_CR103","doi-asserted-by":"crossref","unstructured":"Naudin CR, Maner-Smith K, Owens JA, Wynn GM, Robinson BS, Matthews JD et al. Lactococcus lactis Subspecies cremoris Elicits Protection Against Metabolic Changes Induced by a Western-Style Diet. Gastroenterology. (2020) 159:639\u201351. doi: 10.1053\/j.gastro.2020.03.010","DOI":"10.1053\/j.gastro.2020.03.010"},{"key":"1199_CR104","doi-asserted-by":"publisher","first-page":"2310","DOI":"10.1002\/oby.20330","volume":"21","author":"PG Cano","year":"2013","unstructured":"Cano PG, Santacruz A, Trejo FM, Sanz Y (2013) Bifidobacterium CECT 7765 improves metabolic and immunological alterations associated with obesity in highfat diet-fed mice. Obesity 21:2310\u201321. https:\/\/doi.org\/10.1002\/oby.20330","journal-title":"Obesity"},{"key":"1199_CR105","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2017.01804","volume":"8","author":"W Wu","year":"2017","unstructured":"Wu W, Lv L, Shi D, Ye J, Fang D, Guo F et al (2017) Protective effect of Akkermansia muciniphila against immune-mediated liver injury in a mouse model. Front Microbiol 8:1804. https:\/\/doi.org\/10.3389\/fmicb.2017.01804","journal-title":"Front Microbiol"},{"key":"1199_CR106","doi-asserted-by":"crossref","unstructured":"Alisi A, Bedogni G, Baviera G, Giorgio V, Porro E, Paris C et al. Randomised clinical trial: The beneficial effects of VSL3 in obese children with non-alcoholic steatohepatitis. Aliment Pharmacol Ther. (2014) 39:1276\u201385. doi: 10.1111\/apt.12758","DOI":"10.1111\/apt.12758"},{"key":"1199_CR107","doi-asserted-by":"crossref","unstructured":"Rong L, Ch\u2019ng D, Jia P, Tsoi KKF, Wong SH, Sung JJY. Use of probiotics, prebiotics, and synbiotics in non-alcoholic fatty liver disease: A systematic review and meta-analysis. J Gastroenterol Hepatol. (2023) 38:1682\u201394. doi: 10.1111\/jgh.16256","DOI":"10.1111\/jgh.16256"},{"key":"1199_CR108","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/1484598","author":"MW Xiao","year":"2019","unstructured":"Xiao MW, Lin SX, Shen ZH, Luo WW, Wang XY (2019) Systematic review with meta-analysis: the effects of probiotics in nonalcoholic fatty liver disease. Gastroenterol Res Pract. https:\/\/doi.org\/10.1155\/2019\/1484598","journal-title":"Gastroenterol Res Pract"},{"key":"1199_CR109","doi-asserted-by":"crossref","unstructured":"Davani-Davari D, Negahdaripour M, Karimzadeh I, Seifan M, Mohkam M, Masoumi SJ, Berenjian A, Ghasemi Y. Prebiotics: Definition, Types, Sources, Mechanisms, and Clinical Applications. Foods. 2019 Mar 9;8(3):92. doi: 10.3390\/foods8030092.","DOI":"10.3390\/foods8030092"},{"key":"1199_CR110","doi-asserted-by":"crossref","unstructured":"Yoo S, Jung SC, Kwak K, Kim JS. The Role of Prebiotics in Modulating Gut Microbiota: Implications for Human Health. Int J Mol Sci. 2024 Apr 29;25(9):4834. doi: 10.3390\/ijms25094834.","DOI":"10.3390\/ijms25094834"},{"key":"1199_CR111","doi-asserted-by":"crossref","unstructured":"Louis P, Flint HJ, Michel C. How to manipulate the microbiota: prebiotics. Adv Exp Med Biol. (2016) 902:119\u201342. doi: 10.1007\/978-3-319-31248-4_9","DOI":"10.1007\/978-3-319-31248-4_9"},{"key":"1199_CR112","doi-asserted-by":"crossref","unstructured":"Takai A, Kikuchi K, Ichimura M, Tsuneyama K, Moritoki Y, Matsumoto K et al. Fructo-oligosaccharides ameliorate steatohepatitis, visceral adiposity, and associated chronic inflammation via increased production of short-chain fatty acids in a mouse model of non-alcoholic steatohepatitis. BMC Gastroenterol. (2020) 20:46. doi: 10.1186\/s12876-020-01194-2","DOI":"10.1186\/s12876-020-01194-2"},{"key":"1199_CR113","doi-asserted-by":"crossref","unstructured":"Yu R, Yin Y, Cao M, Ye D, Zhang Y, Zhou Q et al. Fructo-oligosaccharides lower serum lipid levels and suppress high-fat\/high-sugar diet-induced inflammation by elevating serum and gut levels of short-chain fatty acids. J Int Med Res. (2020) 48:300060519896714. doi: 10.1177\/0300060519896714","DOI":"10.1177\/0300060519896714"},{"key":"1199_CR114","doi-asserted-by":"crossref","unstructured":"Matsumoto K, Ichimura M, Tsuneyama K, Moritoki Y, Tsunashima H, Omagari K et al. Fructo-oligosaccharides and intestinal barrier function in a methionine-choline-deficient mouse model of nonalcoholic steatohepatitis. PloS One. (2017) 12:e0175406. doi: 10.1371\/journal.pone.0175406","DOI":"10.1371\/journal.pone.0175406"},{"key":"1199_CR115","doi-asserted-by":"crossref","unstructured":"Weitkunat K, Schumann S, Petzke KJ, Blaut M, Loh G, Klaus S. Effects of dietary inulin on bacterial growth, short-chain fatty acid production and hepatic lipid metabolism in gnotobiotic mice. J Nutr Biochem. (2015) 26:929\u201337. doi: 10.1016\/j.jnutbio.2015.03.010","DOI":"10.1016\/j.jnutbio.2015.03.010"},{"key":"1199_CR116","doi-asserted-by":"crossref","unstructured":"116. Beisner J, Filipe Rosa L, Kaden-Volynets V, Stolzer I, G\u00fcnther C, Bischoff SC. Prebiotic inulin and sodium butyrate attenuate obesity-induced intestinal barrier dysfunction by induction of antimicrobial peptides. Front Immunol. (2021) 12:678360. doi: 10.3389\/fimmu.2021.678360","DOI":"10.3389\/fimmu.2021.678360"},{"key":"1199_CR117","doi-asserted-by":"crossref","unstructured":"Chong CYL, Orr D, Plank LD, Vatanen T, O\u2019Sullivan JM, Murphy R. Randomised double-blind placebo-controlled trial of inulin with metronidazole in non-alcoholic fatty liver disease (NAFLD). Nutrients. (2020) 12:937. doi: 10.3390\/nu12040937","DOI":"10.3390\/nu12040937"},{"key":"1199_CR118","doi-asserted-by":"crossref","unstructured":"Yang Z, Su H, Lv Y, Tao H, Jiang Y, Ni Z et al. Inulin intervention attenuates hepatic steatosis in rats via modulating gut microbiota and maintaining intestinal barrier function. Food Res Int. (2023) 163:112309. doi: 10.1016\/j.foodres.2022.112309","DOI":"10.1016\/j.foodres.2022.112309"},{"key":"1199_CR119","doi-asserted-by":"crossref","unstructured":"Wang R, Ren Y, Bao T, Wang T, Li Y, Liu Y et al. Inulin activates FXR-FGF15 signaling and further increases bile acids excretion in non-alcoholic fatty liver disease mice. Biochem Biophys Res Commun. (2022) 600:156\u201362. doi: 10.1016\/j.bbrc.2022.02.033","DOI":"10.1016\/j.bbrc.2022.02.033"},{"key":"1199_CR120","doi-asserted-by":"crossref","unstructured":"P\u00e9rez-Monter C, \u00c1lvarez-Arce A, Nu\u00f1o-Lambarri N, Escalona-N\u00e1ndez I, Ju\u00e1rez-Hern\u00e1ndez E, Ch\u00e1vez-Tapia NC et al. Inulin improves diet-induced hepatic steatosis and increases intestinal akkermansia genus level. Int J Mol Sci. (2022) 23:991. doi: 10.3390\/ijms23020991","DOI":"10.3390\/ijms23020991"},{"key":"1199_CR121","doi-asserted-by":"publisher","unstructured":"Reshef N, Gophna U, Reshef L, Konikoff F, Gabay G, Zornitzki T et al (2024). Prebiotic treatment in patients with nonalcoholic fatty liver disease (NAFLD)-A randomized pilot trial. Nutrients 16:1571. https:\/\/doi.org\/10.3390\/nu16111571","DOI":"10.3390\/nu16111571"},{"key":"1199_CR122","doi-asserted-by":"publisher","unstructured":"Zhang C, Fang T, Shi L, Wang Y, Deng X, Wang J, Zhou Y (2024). The synbiotic combination of probiotics and inulin improves NAFLD though modulating gut microbiota. The Journal of Nutritional Biochemistry. 125:109546. https:\/\/doi.org\/10.1016\/j.jnutbio.2023.109546","DOI":"10.1016\/j.jnutbio.2023.109546"},{"key":"1199_CR123","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.clnesp.2020.06.020","volume":"39","author":"K Abhari","year":"2020","unstructured":"Abhari K, Saadati S, Yari Z, Hosseini H, Hedayati M, Abhari S, Alavian SM, Hekmatdoost A (2020) The effects of Bacillus coagulans supplementation in patients with non-alcoholic fatty liver disease: a randomized, placebo-controlled, clinical trial. Clin Nutr ESPEN 39:53\u201360","journal-title":"Clin Nutr ESPEN"},{"key":"1199_CR124","doi-asserted-by":"publisher","unstructured":"Scorletti E, Afolabi PR, Miles EA, Smith DE, Almehmadi A, Alshathry A, Childs CE, Del Fabbro S, Bilson J, Moyses HE, Clough GF, Sethi JK, Patel J, Wright M, Breen DJ, Peebles C, Darekar A, Aspinall R, Fowell AJ, Dowman JK, Nobili V, Targher G, Delzenne NM, Bindels LB, Calder PC, Byrne CD (2020). Synbiotics Alter Fecal Microbiomes, But Not Liver Fat or Fibrosis, in a Randomized Trial of Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology 158(6):1597\u20131610.e7. https:\/\/doi.org\/10.1053\/j.gastro.2020.01.031.","DOI":"10.1053\/j.gastro.2020.01.031"},{"key":"1199_CR125","doi-asserted-by":"publisher","unstructured":"Rivero-Guti\u00e9rrez B, G\u00e1mez-Belmonte R, Su\u00e1rez MD, Lav\u00edn JL, Aransay AM, Olivares M, Mart\u00ednez-Augustin O, S\u00e1nchez de Medina F, Zarzuelo A (2017). A synbiotic composed of Lactobacillus fermentum CECT5716 and FOS prevents the development of fatty acid liver and glycemic alterations in rats fed a high fructose diet associated with changes in the microbiota. Mol Nutr Food Res 61(8).\u00a0Epub 2017 Jun 8.\u00a0https:\/\/doi.org\/10.1002\/mnfr.201600622","DOI":"10.1002\/mnfr.201600622"},{"key":"1199_CR126","doi-asserted-by":"publisher","unstructured":"Ju\u00e1rez-Fern\u00e1ndez, M, Porras D, Petrov P, Rom\u00e1n-Sag\u00fcillo S, Garc\u00eda-Mediavilla MV, Soluyanova P, Mart\u00ednez-Fl\u00f3rez S, Gonz\u00e1lez-Gallego J, Nistal E, Jover R et al (2021). The Synbiotic Combination of Akkermansia muciniphila and Quercetin Ameliorates Early Obesity and NAFLD through Gut Microbiota Reshaping and Bile Acid Metabolism Modulation. Antioxidants\u00a010:2001. https:\/\/doi.org\/10.3390\/antiox10122001","DOI":"10.3390\/antiox10122001"},{"key":"1199_CR127","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2024.107398","author":"V Musazadeh","year":"2024","unstructured":"Musazadeh V, Assadian K, Rajabi F, Faghfouri AH, Soleymani Y, Kavyani Z, Najafiyan B (2024) The effect of synbiotics on liver enzymes, obesity indices, blood pressure, lipid profile, and inflammation in patients with non-alcoholic fatty liver: a systematic review and meta-analysis of randomized controlled trials. Pharmacol Res. https:\/\/doi.org\/10.1016\/j.phrs.2024.107398","journal-title":"Pharmacol Res"},{"key":"1199_CR128","doi-asserted-by":"publisher","unstructured":"Han H, Jiang Y, Wang M, Melaku M, Liu L, Zhao Y, Zhang H (2021). Intestinal dysbiosis in nonalcoholic fatty liver disease (NAFLD): focusing on the gut\u2013liver axis. Critical Reviews in Food Science and Nutrition, 63(12), 1689\u20131706. https:\/\/doi.org\/10.1080\/10408398.2021.1966738","DOI":"10.1080\/10408398.2021.1966738"},{"key":"1199_CR129","doi-asserted-by":"publisher","unstructured":"Yao F, Jia R, Huang H, Yu Y, Mei L, Bai L, Ding Y, Zheng P (2019). Effect of Lactobacillus paracasei N1115 and fructooligosaccharides in nonalcoholic fatty liver disease. Arch Med Sci 15(5):1336\u20131344. https:\/\/doi.org\/10.5114\/aoms.2019.86611.","DOI":"10.5114\/aoms.2019.86611"},{"key":"1199_CR130","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2023","volume":"151","author":"J Bilson","year":"2024","unstructured":"Bilson J, Oquendo CJ, Read J, Scorletti E, Afolabi PR, Lord J, Bindels LB, Targher G, Mahajan S, Baralle D, Calder PC, Byrne CD, Sethi JK (2024) Markers of adipose tissue fibrogenesis associate with clinically significant liver fibrosis and are unchanged by synbiotic treatment in patients with NAFLD. Metabolism. 151:155759. https:\/\/doi.org\/10.1016\/j.metabol.2023","journal-title":"Metabolism."},{"key":"1199_CR131","doi-asserted-by":"publisher","unstructured":"Scorletti E, Afolabi PR, Miles EA, Smith DE, Almehmadi A, Alshathry A, Childs CE, Del Fabbro S, Bilson J, Moyses HE, Clough GF (2020). Synbiotics alter fecal microbiomes, but not liver fat or fibrosis, in a randomized trial of patients with nonalcoholic fatty liver disease. Gastroenterology 158(6):1597\u2013610. https:\/\/doi.org\/10.1053\/j.gastro.2020.01.031","DOI":"10.1053\/j.gastro.2020.01.031"},{"key":"1199_CR132","doi-asserted-by":"publisher","unstructured":"Pan Y, Yang Y, Wu J\u00a0et al (2024). Efficacy of probiotics, prebiotics, and synbiotics on liver enzymes, lipid profiles, and inflammation in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis of randomized controlled trials. BMC Gastroenterol 24:283. https:\/\/doi.org\/10.1186\/s12876-024-03356-y","DOI":"10.1186\/s12876-024-03356-y"},{"key":"1199_CR133","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.655268","volume":"8","author":"Y Yang","year":"2021","unstructured":"Yang Y, Zhao Y, Zhang L et al (2021) The application of mesenchymal stem cells in the treatment of liver diseases: mechanism, efficacy, and safety issues. Front Med 8:655268","journal-title":"Front Med"},{"key":"1199_CR134","doi-asserted-by":"publisher","unstructured":"Wang JL, Ding HR, Pan CY\u00a0et al\u00a0(2021). Mesenchymal stem cells ameliorate lipid metabolism through reducing mitochondrial damage of hepatocytes in the treatment of post-hepatectomy liver failure. Cell Death Dis 12:111. https:\/\/doi.org\/10.1038\/s41419-020-03374-0","DOI":"10.1038\/s41419-020-03374-0"},{"key":"1199_CR135","doi-asserted-by":"publisher","unstructured":"Chen Y, Yang F, Wang Y\u00a0et al\u00a0(2025). Mesenchymal stem cell-derived small extracellular vesicles reduced hepatic lipid accumulation in MASLD by suppressing mitochondrial fission. Stem Cell Res Ther. 16:116. https:\/\/doi.org\/10.1186\/s13287-025-04228-2","DOI":"10.1186\/s13287-025-04228-2"},{"key":"1199_CR136","doi-asserted-by":"publisher","unstructured":"Zou X, Brigstock D (2024). Extracellular Vesicles from Mesenchymal Stem Cells: Potential as Therapeutics in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). Biomedicines 12(12):2848. https:\/\/doi.org\/10.3390\/biomedicines12122848","DOI":"10.3390\/biomedicines12122848"},{"key":"1199_CR137","doi-asserted-by":"publisher","unstructured":"Fujiki J, Schnabl B (2023). Phage therapy: Targeting intestinal bacterial microbiota for the treatment of liver diseases. Jhep Reports 5(12):100909. https:\/\/doi.org\/10.1016\/j.jhepr.2023.100909","DOI":"10.1016\/j.jhepr.2023.100909"},{"key":"1199_CR138","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1038\/s41586-019-1742-x","volume":"575","author":"Y Duan","year":"2019","unstructured":"Duan Y, Llorente C, Lang S, Brandl K, Chu H, Jiang L, White RC, Clarke TH, Nguyen K, Torralba M et al (2019) Bacteriophage targeting of gut bacterium attenuates alcoholic liver disease. Nature 575:505\u2013511","journal-title":"Nature"},{"key":"1199_CR139","unstructured":"Duan Y, Llorente C, Lang S, Brandl K, Chu H, Jiang L et al (2019). Bacteriophage targeting of cytolysin-positive Enterococcus faecalis reduces alcohol-induced liver disease in mice. Nature\u00a0575(7783):505\u2013511."},{"key":"1199_CR140","doi-asserted-by":"publisher","unstructured":"Koning M, Herrema H, Nieuwdorp M, Meijnikman AS (2023). Targeting nonalcoholic fatty liver disease via gut microbiome-centered therapies. Gut Microbes 15(1):2226922. https:\/\/doi.org\/10.1080\/19490976.2023.2226922","DOI":"10.1080\/19490976.2023.2226922"},{"key":"1199_CR141","doi-asserted-by":"publisher","unstructured":"Gan L, Feng Y, Du B\u00a0et al\u00a0(2023). Bacteriophage targeting microbiota alleviates non-alcoholic fatty liver disease induced by high alcohol-producing Klebsiella pneumoniae. Nat Commun\u00a014:3215. https:\/\/doi.org\/10.1038\/s41467-023-39028-w","DOI":"10.1038\/s41467-023-39028-w"},{"key":"1199_CR142","doi-asserted-by":"publisher","unstructured":"Craven L, Rahman A, Nair Parvathy S, Beaton M, Silverman J, Qumosani K, Hramiak I, Hegele R, Joy T, Meddings J, Urquhart B, Harvie R, McKenzie C, Summers K, Reid G, Burton JP, Silverman M (2020) Allogenic Fecal Microbiota Transplantation in Patients With Nonalcoholic Fatty Liver Disease Improves Abnormal Small Intestinal Permeability: A Randomized Control Trial. Am J Gastroenterol 115(7):1055\u20131065. https:\/\/doi.org\/10.14309\/ajg.0000000000000661","DOI":"10.14309\/ajg.0000000000000661"},{"issue":"1","key":"1199_CR143","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-01751-y","volume":"7","author":"D Zhou","year":"2017","unstructured":"Zhou D, Pan Q, Shen F, Cao HX, Ding WJ, Chen YW, Fan JG (2017) Total fecal microbiota transplantation alleviates high-fat diet-induced steatohepatitis in mice via beneficial regulation of gut microbiota. Sci Rep 7(1):1529. https:\/\/doi.org\/10.1038\/s41598-017-01751-y","journal-title":"Sci Rep"},{"key":"1199_CR144","doi-asserted-by":"publisher","unstructured":"Arab JP, Karpen SJ, Dawson PA, Arrese M, Trauner M (2017). Bile acids and nonalcoholic fatty liver disease: Molecular insights and therapeutic perspectives. Hepatology. 65(1):350\u2013362. https:\/\/doi.org\/10.1002\/hep.28709","DOI":"10.1002\/hep.28709"},{"key":"1199_CR145","doi-asserted-by":"publisher","unstructured":"Witjes JJ, Smits LP, Pekmez CT, Prodan A, Meijnikman AS, Troelstra MA, Bouter KEC, Herrema H, Levin E, Holleboom AG, Winkelmeijer M, Beuers UH, van Lienden K, Aron-Wisnewky J, Mannisto V, Bergman JJ, Runge JH, Nederveen AJ, Dragsted LO, Konstanti P, Zoetendal EG, de Vos W, Verheij J, Groen AK, Nieuwdorp M (2020). Donor Fecal Microbiota Transplantation Alters Gut Microbiota and Metabolites in Obese Individuals With Steatohepatitis. Hepatol Commun 4(11):1578\u20131590. https:\/\/doi.org\/10.1002\/hep4.1601","DOI":"10.1002\/hep4.1601"},{"key":"1199_CR146","doi-asserted-by":"publisher","unstructured":"Bajaj JS, Kassam Z, Fagan A, Gavis EA, Liu E, Cox IJ, Kheradman R, Heuman D, Wang J, Gurry T, Williams R, Sikaroodi M, Fuchs M, Alm E, John B, Thacker LR, Riva A, Smith M, Taylor-Robinson SD, Gillevet PM (2017). Fecal microbiota transplant from a rational stool donor improves hepatic encephalopathy: A randomized clinical trial. Hepatology 66(6):1727\u20131738. https:\/\/doi.org\/10.1002\/hep.29306","DOI":"10.1002\/hep.29306"},{"key":"1199_CR147","doi-asserted-by":"publisher","unstructured":"Ott SJ, Waetzig GH, Rehman A, Moltzau-Anderson J, Bharti R, Grasis JA, Cassidy L, Tholey A, Fickenscher H, Seegert D, Rosenstiel P, Schreiber S (2017). Efficacy of Sterile Fecal Filtrate Transfer for Treating Patients With Clostridium difficile Infection. Gastroenterology 152(4):799\u2013811.e7. https:\/\/doi.org\/10.1053\/j.gastro.2016.11.010","DOI":"10.1053\/j.gastro.2016.11.010"}],"container-title":["Journal of Physiology and Biochemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13105-026-01199-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13105-026-01199-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13105-026-01199-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T08:04:44Z","timestamp":1788595484000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13105-026-01199-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,5]]},"references-count":147,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["1199"],"URL":"https:\/\/doi.org\/10.1007\/s13105-026-01199-7","relation":{},"ISSN":["1138-7548","1877-8755"],"issn-type":[{"value":"1138-7548","type":"print"},{"value":"1877-8755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,5]]},"assertion":[{"value":"26 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethical approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"NA.","order":3,"name":"Ethics","label":"Clinical trial number","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"89"}}